| Literature DB >> 28905530 |
Myoung Kyu Lee1, Hyoung Kyu Yoon2, Sei Won Kim3, Tae Hyung Kim4, Seoung Ju Park5, Young Min Lee6.
Abstract
Bronchial asthma is a disease characterized by the condition of airway hyper-responsiveness, which serves to produce narrowing of the airway secondary to airway inflammation and/or various spasm-inducing stimulus. Nonspecific bronchoprovocation testing is an important method implemented for the purpose of diagnosing asthma; this test measures the actual degree of airway hyper-responsiveness and utilizes direct and indirect bronchoprovocation testing. Direct bronchoprovocation testing using methacholine or histamine may have superior sensitivity as these substances directly stimulate the airway smooth muscle cells. On the other hand, this method also engenders the specific disadvantage of relatively low specificity. Indirect bronchoprovocation testing using mannitol, exercise, hypertonic saline, adenosine and hyperventilation serves to produce reactions in the airway smooth muscle cells by liberating mediators with stimulation of airway inflammatory cells. Therefore, this method has the advantage of high specificity and also demonstrates relatively low sensitivity. Direct and indirect testing both call for very precise descriptions of very specific measurement conditions. In addition, it has become evident that challenge testing utilizing each of the various bronchoconstrictor stimuli requires distinct and specific protocols. It is therefore important that the clinician understand the mechanism by which the most commonly used bronchoprovocation testing works. It is important that the clinician understand the mechanism of action in the testing, whether direct stimuli (methacholine) or indirect stimuli (mannitol, exercise) is implemented, when the testing is performed and the results interpreted. Copyright©2017. The Korean Academy of Tuberculosis and Respiratory Diseases.Entities:
Keywords: Airway Hyper-responsiveness; Bronchial Asthma; Bronchial Provocation Tests
Year: 2017 PMID: 28905530 PMCID: PMC5617850 DOI: 10.4046/trd.2017.0051
Source DB: PubMed Journal: Tuberc Respir Dis (Seoul) ISSN: 1738-3536
Indications and contraindications of bronchoprovocation test
| Indications |
| Diagnosis of asthma (airway hyperresponsiveness) |
| Airway hyperresponsiveness severity assessment |
| Determining relative risk of asthma |
| Response assessment of asthma treatment |
| Absolute contraindications |
| Severe airflow limitation (FEV1 <50% of predicted normal value or <1.0 L) |
| Myocardial infarction or ischemic stroke during the past 3 months |
| Diagnosed aneurysm |
| Relative contraindications |
| Moderate airflow limitation (FEV1 <60% of predicted normal value) |
| Acute exacerbation of asthma |
| Recent upper respiratory tract infection within 2 weeks |
| Uncontrolled hypertension |
| Pregnancy or breast-feeding |
| Epilepsy requiring medications |
| If spirometry measurement cannot be performed in acceptable level |
FEV1: forced expiratory volume at 1 second.
Overview of direct and indirect stimuli
| Stimulus | |
|---|---|
| Direct stimuli | Cholinergic agonist (methacholine, etc.) |
| Histamine | |
| Prostaglandin D2 | |
| Leukotriene C4/D4/E4 | |
| Indirect stimuli | Physical stimuli |
| Exercise | |
| Anisotonic spray (hypertonic or hypotonic distilled water, mannitol) | |
| Hyperventilation under dry atmosphere | |
| Drug stimuli | |
| Adenosine | |
| Tachykinins | |
| Bradykinin | |
| Metabisulphite/SO2 | |
| Propranolol | |
| Endotoxin (LPS) | |
| Platelet activating factor | |
| Ozone | |
| Specific drugs | |
| Aspirin, NSAIDs | |
| Allergen |
SO2: sulphur dioxide; LPS: lipopolysaccharides; NSAIDs: nonsteroidal anti-inflammatory drugs.
Factors that decrease bronchial responsiveness
| Factor | Minimum time intervals from the last dose to test |
|---|---|
| Drugs | |
| Short-acting inhaled β2 agonists (isoproterenol, metaproterenol, albuterol, terbutaline) | 8 hr |
| Short-acting inhaled anticholinergics (ipratropium) | 24 hr |
| Long-acting inhaled bronchodilators (salmeterol, formoterol, tiotropium) | 48 hr (more than 1 wk in case of tiotropium) |
| Oral bronchodilators | |
| Medium-acting theophylline | 24 hr |
| Long-acting theophylline | 48 hr |
| Oral β2 agonists | 12 hr |
| Long-acting oral β2 agonists | 24 hr |
| Cromolyn sodium | 8 hr |
| Nedocromil | 48 hr |
| Hydroxyzine, cetirizine | 3 days |
| Leukotriene modifiers | 24 hr |
| Corticosteroids (oral or inhaled) | Duration of action is unknown. It should be suspended for weeks to eliminate anti-inflammatory effect. |
| Foods | |
| Coffee, tea, cola, chocolate | On the day of test |
Factors that increase bronchial responsiveness
| Factor | Duration of action |
|---|---|
| Exposure to environmental antigens | 1–3 wk |
| Exposed to occupational causes | Several months |
| Respiratory infections | 3–6 wk |
| Air pollution | 1 wk |
| Smoking | Not sure |
| Chemical stimuli | Several days to several months |